ImageneBio successfully completed a reverse merger with Ikena Oncology, raising $75 million through PIPE financing and positioning itself for growth in the immunology and inflammation sector.

Information on the Target

ImageneBio, previously known as 创响生物, has recently completed a reverse merger with Ikena Oncology, leading to its public listing on NASDAQ under the ticker symbol NASDAQ:IMA. The company finalized this merger on July 28, 2025, and has successfully raised a total of $75 million through a PIPE (Private Investment in Public Equity) financing round. This round saw participation from leading international life science investors such as OrbiMed, Deep Track, Foresite, RTW, BVF, Blue Owl, and Omega, showcasing a strong market confidence in ImageneBio's potential and future growth.

ImageneBio’s core asset is the OX40-targeting monoclonal antibody, IMG-007, which is currently in phase 2b clinical trials aimed at treating moderate to severe atopic dermatitis. The company has secured over $175 million in funding through the reverse merger and PIPE financing, allowing it to further develop its innovative pipeline and expand into other immune-related indications.

Industry Overview in the Target's Specific Country

The biotechnology sector in the United States continues to thrive, driven by rapid advancements in technology and a growing emphasis on personalized medicine. With substantial investment flowing into research and development, biotech firms are increasin